- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels - Nurtec ODT Label Expanded to include Lactation Data in the ...

NEW HAVEN, Conn., Jan. 25, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late ...

Biohavan’s Nurtec ODT has a new indication. The drug has received the Food and Drug Administration’s approval for the preventive treatment of migraine. The product, first approved in February 2020 to ...

NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC™ ODT ...

Khloé Kardashian is headlining a TV spot for Biohaven’s Nurtec ODT that is designed to make the drug stand out in the crowded migraine field. But the stakes are higher now than they were two years ago ...

Nurtec ODT (rimegepant) is a prescription drug that’s used to treat and help prevent migraine. Nurtec ODT comes as an orally disintegrating tablet. Nurtec ODT is a brand-name medication. It contains ...

- Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020 NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- ...